Johnson & Johnson Price to Free Cash Flow Ratio 2010-2024 | JNJ
Historical price to free cash flow ratio values for Johnson & Johnson (JNJ) since 2010.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Johnson & Johnson Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
| 2024-04-17 |
144.77 |
|
19.92 |
| 2023-12-31 |
155.56 |
$7.27 |
21.41 |
| 2023-09-30 |
153.36 |
$6.28 |
24.42 |
| 2023-06-30 |
161.82 |
$5.63 |
28.77 |
| 2023-03-31 |
150.39 |
$6.23 |
24.13 |
| 2022-12-31 |
170.20 |
$6.65 |
25.58 |
| 2022-09-30 |
156.39 |
$6.80 |
23.01 |
| 2022-06-30 |
168.80 |
$9.31 |
18.13 |
| 2022-03-31 |
167.48 |
$9.01 |
18.58 |
| 2021-12-31 |
160.62 |
$10.36 |
15.51 |
| 2021-09-30 |
150.63 |
$11.59 |
13.00 |
| 2021-03-31 |
151.44 |
$8.14 |
18.60 |
| 2020-12-31 |
144.12 |
$7.67 |
18.78 |
| 2020-09-30 |
135.38 |
$6.91 |
19.59 |
| 2020-06-30 |
127.04 |
$6.65 |
19.11 |
| 2020-03-31 |
117.63 |
$8.50 |
13.83 |
| 2019-12-31 |
130.01 |
$8.64 |
15.05 |
| 2019-09-30 |
114.52 |
$11.46 |
9.99 |
| 2019-06-30 |
123.28 |
$6.74 |
18.29 |
| 2019-03-31 |
122.89 |
$5.81 |
21.14 |
| 2018-12-31 |
112.71 |
$6.88 |
16.39 |
| 2021-06-30 |
152.74 |
$3.20 |
47.72 |
| 2018-09-30 |
119.91 |
$7.48 |
16.04 |
| 2018-06-30 |
104.60 |
$7.70 |
13.58 |
| 2018-03-31 |
109.66 |
$7.36 |
14.89 |
| 2017-12-31 |
118.81 |
$7.14 |
16.63 |
| 2017-09-30 |
109.88 |
$7.11 |
15.45 |
| 2017-06-30 |
111.10 |
$6.62 |
16.78 |
| 2017-03-31 |
103.92 |
$6.33 |
16.42 |
| 2016-12-31 |
95.50 |
$6.03 |
15.85 |
| 2016-09-30 |
97.25 |
$5.86 |
16.58 |
| 2016-06-30 |
99.20 |
$6.19 |
16.02 |
| 2016-03-31 |
87.86 |
$6.66 |
13.20 |
| 2015-12-31 |
82.81 |
$6.96 |
11.90 |
| 2015-09-30 |
74.71 |
$6.13 |
12.19 |
| 2015-06-30 |
77.39 |
$6.80 |
11.38 |
| 2015-03-31 |
79.31 |
$6.56 |
12.09 |
| 2014-12-31 |
81.86 |
$6.85 |
11.95 |
| 2014-09-30 |
82.91 |
$6.76 |
12.27 |
| 2014-06-30 |
80.83 |
$5.83 |
13.88 |
| 2014-03-31 |
75.37 |
$5.49 |
13.72 |
| 2013-12-31 |
69.77 |
$4.96 |
14.06 |
| 2013-09-30 |
65.58 |
$4.94 |
13.29 |
| 2013-06-30 |
64.47 |
$4.71 |
13.68 |
| 2013-03-31 |
60.76 |
$4.64 |
13.09 |
| 2012-12-31 |
51.83 |
$4.97 |
10.43 |
| 2012-09-30 |
50.51 |
$5.02 |
10.06 |
| 2012-06-30 |
49.07 |
$5.05 |
9.71 |
| 2012-03-31 |
47.45 |
$4.83 |
9.83 |
| 2011-12-31 |
46.77 |
$4.59 |
10.18 |
| 2011-09-30 |
45.00 |
$4.62 |
9.73 |
| 2011-06-30 |
46.59 |
$4.71 |
9.89 |
| 2011-03-31 |
41.14 |
$4.72 |
8.72 |
| 2010-12-31 |
42.56 |
$5.21 |
8.17 |
| 2010-09-30 |
42.27 |
$5.76 |
7.34 |
| 2010-06-30 |
39.91 |
$5.69 |
7.02 |
| 2010-03-31 |
43.66 |
$5.50 |
7.93 |
| 2009-12-31 |
42.81 |
$5.15 |
8.31 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$348.093B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
